Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has scheduled a conference call for 4th August 2020 at 4:30 PM Eastern Time to announce its 2Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.deciphera.com
Earnings Expectation
Deciphera Pharmaceuticals, Inc. is expected to report second quarter earnings results, after market close, on Tuesday 4th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 1.37 per share from revenue of $ 0.89 million. Looking ahead, the full year loss are expected at $ 5.57 per share on the revenues of $ 11.91 million.
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The companys lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors.
